Last updated: February 25, 2026
What is the Product?
NDC 69452-0363 corresponds to Xyosted (testosterone enanthate) injection. Approved by the FDA in 2018, Xyosted is indicated for testosterone replacement therapy in adult men with documented hypogonadism.
Market Context
The testosterone replacement market targets men with low testosterone levels, a condition affecting approximately 4 to 5 million men in the U.S. (NCHS, 2020). The market's primary competitors include injectable testosterone formulations, gels, patches, and pellets.
Market Size and Growth
| Metric |
Data |
Source |
| US hypogonadism prevalence |
4-5 million men |
[1] |
| Testosterone therapy market size (2022) |
$1.8 billion |
[2] |
| Annual growth rate |
5.2% |
[2] |
The injectable segment accounts for roughly 35-40% of the total market.
Competitive Landscape
Major competitors include:
- Testosterone Cypionate and Enanthate: Widely prescribed, lower-cost options.
- AndroGel and Testim (gels): Popular topical therapies.
- Axiron (gel), Depo-Testosterone (injectable): Other formulations.
Xyosted's unique position is as a quicker-to-absorb, more controlled dosing injectable.
Pricing History and Trends
- Initial launch price (2018): Approximately $730 per 10 mL vial (100 mg/mL concentration) based on wholesale acquisition cost (WAC).
- Current average wholesale price (2023): ~$780 per 10 mL vial.
- Price trend: Slight increase (~1-2%) annually, in line with inflation and manufacturing cost inflation.
Price Projection Models
Conservative Scenario
Given market maturity:
- 2024: $800 per vial (+2.5%).
- 2025: $820 per vial (+2.5%).
Aggressive Scenario
Assuming increased adoption due to favorable dosing and patient compliance:
- 2024: $850 per vial (+4%).
- 2025: $885 per vial (+4%).
Market Penetration and Volume Expectations
- Peak annual utilization: approximately 250,000–300,000 units in the U.S.
- Market share: Expected to reach 3-5% of the hypogonadism population within five years.
Regulatory and Pricing Influences
- Insurance reimbursement: Changes can influence net pricing.
- Pricing pressures: Cost-containment strategies by payers could moderate price increases.
- Patent status: Patent expiration (if applicable) impacts generics entry and prices.
Key Factors Affecting Future Prices
- Market competition: Entry of biosimilars can drive prices down.
- Manufacturing costs: Sustained or increased regulatory standards may increase costs.
- Reimbursement policies: Shifts favoring less expensive or alternative therapies.
Summary
- Current average wholesale price (AWP) is approximately $780 per 10 mL vial.
- Price projections suggest a modest increase (~2-4%) annually over the next 2 years.
- Market volume is poised for gradual growth driven by physician adoption and patient preference for injectable therapy.
- Competitive pressures and regulatory factors will influence final pricing dynamics.
Key Takeaways
- NDC 69452-0363 (Xyosted) holds a niche in testosterone replacement therapy, with limited direct competition.
- Prices are expected to increase modestly in the near term, influenced by market maturity and competitive forces.
- Growth in market volume is driven by the adoption of injectable testosterone formulations.
- Price sensitivity among payers and the entry of biosimilars could reduce prices over the long term.
FAQs
1. How does Xyosted’s pricing compare to other testosterone therapies?
It is priced slightly higher than traditional injectable forms like testosterone cypionate but lower than some branded gels or patches.
2. What factors could accelerate price declines?
Introduction of biosimilars, increased reimbursement restrictions, and greater market saturation.
3. Is there any patent protection that preserves pricing?
No current patent restrictions beyond the original patent period. Patent expiration typically leads to generic competition.
4. How does patient preference affect the market?
Patients favor therapies with convenient dosing, impacting adoption and potentially influencing pricing strategies.
5. What role do insurance providers play in pricing?
Reimbursement rates influence net prices; payers may negotiate discounts or prefer alternative therapies, affecting Xyosted’s market share and pricing.
References
[1] Mayer, E. A., et al. (2020). Prevalence of hypogonadism in men. The Journal of Clinical Endocrinology & Metabolism, 105(3), 1-12.
[2] Grand View Research. (2022). Testosterone replacement therapy market size, share & trends analysis. Retrieved from https://www.grandviewresearch.com/industry-analysis/testosterone-replacement-therapy-market
